<DOC>
	<DOCNO>NCT00893061</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Aromatase inhibitor , letrozole , anastrozole , exemestane , may fight breast cancer lower amount estrogen body make . Hormone therapy , use tamoxifen citrate , may fight breast cancer block use estrogen tumor cell . It yet know whether aromatase inhibitor tamoxifen citrate less effect memory patient receive treatment breast cancer . PURPOSE : This randomized phase III trial study letrozole , anastrozole , exemestane see effect memory compare tamoxifen citrate treat postmenopausal woman breast cancer .</brief_summary>
	<brief_title>Letrozole , Anastrozole , Exemestane , Tamoxifen Citrate Treating Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate verbal episodic memory patient breast cancer 6 month treatment aromatase inhibitor ( AI ) v tamoxifen citrate . Secondary - To evaluate cognitive function patient month 6 12 treatment . - To evaluate psychological social impact patient month 6 12 treatment . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral tamoxifen citrate daily 1 year absence disease progression unacceptable toxicity . - Arm II : Patients receive oral aromatase inhibitor ( letrozole , anastrozole , exemestane ) daily 1 year absence disease progression unacceptable toxicity . Patients undergo cognitive , psychological , social , quality life assessment every 6 month use CDS scale , Edinburgh Handedness Inventory , Mini Mental Test , French version National Adult Reading Test , Benton Visual Retention test , direct indirect capacity WAIS-R , WMS sequential visual-spatial capacity , dual task test , categorical formal verbal fluency , Trail make test , Stroop test , Wisconsin Card Sorting test , choice reaction time test , sequential visual spatial capacity , HADS scale , IADL , QLQ-C30 questionnaire . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer No metastatic disease Meets criteria initiate adjuvant endocrine therapy Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive disease PATIENT CHARACTERISTICS : Postmenopausal , define menstruation â‰¥ 1 year , confirm measurement FSH 17betaestradiol Karnofsky performance status 80100 % Native speaker French Beneficiary French Social Security insurance plan No prior cognitive disorder No depression confirm active psychiatric disease Able undergo medical monitoring trial due geographic , social psychological reason No personal family history thromboembolic disease PRIOR CONCURRENT THERAPY : No prior adjuvant chemotherapy No concurrent followup participation another study No concurrent treatment psychotropic substance ( i.e. , long half life benzodiazepine , antipsychotic , anticholinesterase )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>